Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications
Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolism and enhances body recomposition
STOCKHOLM, Sweden, May 24, 2024 — Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism (1). The research paper validates the mechanism of action of the company’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications.
